Literature DB >> 30393596

Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.

Rafael Rosell1, Niki Karachaliou2, Carles Codony-Servat3, Masaoki Ito1,3,4.   

Abstract

Entities:  

Year:  2018        PMID： 30393596      PMCID： PMC6193900          DOI： 10.21037/tlcr.2018.03.20

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  29 in total

1.  AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.

Authors:  Kavitha Balaji; Smruthi Vijayaraghavan; Lauren Averett Byers; Khandan Keyomarsi; Lixia Diao; Pan Tong; Youhong Fan; Jason Pw Carey; Tuyen N Bui; Steve Warner; John V Heymach; Kelly K Hunt; Jing Wang
Journal:  Mol Cancer Res       Date:  2016-09-26       Impact factor: 5.852

2.  Ect2-Dependent rRNA Synthesis Is Required for KRAS-TRP53-Driven Lung Adenocarcinoma.

Authors:  Verline Justilien; Syed A Ali; Lee Jamieson; Ning Yin; Adrienne D Cox; Channing J Der; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2017-01-19       Impact factor: 31.743

3.  c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.

Authors:  Manuel Sanclemente; Sarah Francoz; Laura Esteban-Burgos; Emilie Bousquet-Mur; Magdolna Djurec; Pedro P Lopez-Casas; Manuel Hidalgo; Carmen Guerra; Matthias Drosten; Monica Musteanu; Mariano Barbacid
Journal:  Cancer Cell       Date:  2018-01-27       Impact factor: 31.743

4.  The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma.

Authors:  Verline Justilien; Michael P Walsh; Syed A Ali; E Aubrey Thompson; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

5.  Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.

Authors:  Syed A Ali; Verline Justilien; Lee Jamieson; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

6.  Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.

Authors:  R Rosell; J L González-Larriba; V Alberola; F Molina; M Monzó; D Benito; J M Pérez; J M de Anta
Journal:  Semin Oncol       Date:  1995-12       Impact factor: 4.929

7.  Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers.

Authors:  Laetitia Seguin; Maria F Camargo; Hiromi I Wettersten; Shumei Kato; Jay S Desgrosellier; Tami von Schalscha; Kathryn C Elliott; Erika Cosset; Jacqueline Lesperance; Sara M Weis; David A Cheresh
Journal:  Cancer Discov       Date:  2017-09-11       Impact factor: 39.397

8.  Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy.

Authors:  Kilian V M Huber; Eidarus Salah; Branka Radic; Manuela Gridling; Jonathan M Elkins; Alexey Stukalov; Ann-Sofie Jemth; Camilla Göktürk; Kumar Sanjiv; Kia Strömberg; Therese Pham; Ulrika Warpman Berglund; Jacques Colinge; Keiryn L Bennett; Joanna I Loizou; Thomas Helleday; Stefan Knapp; Giulio Superti-Furga
Journal:  Nature       Date:  2014-04-02       Impact factor: 49.962

9.  YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.

Authors:  G Hua; X Lv; C He; S W Remmenga; K J Rodabough; J Dong; L Yang; S M Lele; P Yang; J Zhou; A Karst; R I Drapkin; J S Davis; C Wang
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

10.  Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Authors:  Rodrigo Romero; Volkan I Sayin; Shawn M Davidson; Matthew R Bauer; Simranjit X Singh; Sarah E LeBoeuf; Triantafyllia R Karakousi; Donald C Ellis; Arjun Bhutkar; Francisco J Sánchez-Rivera; Lakshmipriya Subbaraj; Britney Martinez; Roderick T Bronson; Justin R Prigge; Edward E Schmidt; Craig J Thomas; Chandra Goparaju; Angela Davies; Igor Dolgalev; Adriana Heguy; Viola Allaj; John T Poirier; Andre L Moreira; Charles M Rudin; Harvey I Pass; Matthew G Vander Heiden; Tyler Jacks; Thales Papagiannakopoulos
Journal:  Nat Med       Date:  2017-10-02       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.